Get the ChemPriceHub app — track prices on the go. Membership syncs across app & web. View plans
 
Home > News > Industrial chain autonomy and controllability: identifying bottlenecks, judging ...

Industrial chain autonomy and controllability: identifying bottlenecks, judging the pace of substitution, and a full investment research framework for

Daniel Foster
Published on 2026-11-18

Industrial chain autonomy and controllability: identifying bottlenecks, judging the pace of substitution, and a full investment research framework for

Core risk screening: overcapacity risk in the industry, technology route iteration risk, escalation of overseas trade barriers, and intensifying price wars. New energy as a whole has already entered a mature competitive stage; autonomy and controllability efforts focus only on a few weak links and should not be generalized to the entire industrial chain.

7.5 Pharmaceutical and biotech industrial chain: equal emphasis on innovation and security, with tough battles in high-end devices and upstream consumables

Autonomy and controllability in pharma and biotech serves two goals at once: industrial security and innovation upgrading. Generic drugs and mid- to low-end devices are basically self-sufficient now, but high-end medical devices, upstream research reagents, and consumables still rely heavily on imports.

Core bottleneck links: high-end medical imaging equipment, high-end biological reagents and research consumables, high-end implantable and interventional consumables, high-end intermediates for active pharmaceutical ingredients, and high-end life science instruments.

Substitution progress tiers:

  • First tier: generic drugs, ordinary medical devices, conventional active pharmaceutical ingredients;
  • Second tier: mid- to high-end consumables, ordinary diagnostic reagents, specialty active pharmaceutical ingredients;
  • Third tier: high-end medical imaging equipment, mid- to high-end biological reagents;
  • Fourth tier: high-end life science instruments, high-end implantable and interventional consumables, and raw materials for high-end biologics.

Critical points for technological breakthroughs: core components of high-end imaging equipment developed in-house, biological reagent purity and stability reaching overseas-equivalent levels, and high-end consumables entering mainstream hospital supply chains.

Main A-share investment themes:

  1. High-end medical devices: imaging equipment, minimally invasive devices, etc., with large substitution space and strong policy support;
  2. Upstream biological reagents and consumables: rigid demand for research and industrial production, accelerating domestic substitution, strong growth;
  3. Specialty active pharmaceutical ingredients and high-end intermediates: globally competitive, continuously upgrading toward the high end.

Core risk screening: pressure from centralized procurement policy, R&D failure risk, overseas certification falling short of expectations, and difficulty gaining hospital access. Focus on products' clinical value and hospital entry progress, and watch out for centralized procurement squeezing profit margins.

Chapter 8 Investment research in practice: a stock-picking framework and target screening for the autonomy and controllability theme

8.1 Four-stage stock-picking strategy: differentiated investment logic matched to the pace of substitution

Stock-picking logic for the autonomy and controllability theme must strictly match the substitution stage; the core selection factors are completely different at each stage:

  1. Stock picking during the technology validation period. The core focus is technological barriers and team capability; prioritize leading companies with the most certain technology routes and the strongest R&D. Selection factors: core team's industry background, R&D spending intensity, number of patents held, fit of the technology route. Investment points: diversify positions, control position size, bet on technology breakthrough catalysts, and do not concentrate heavily in a single name.

  2. Stock picking during the customer validation period. The core focus is customer resources and certification progress, capturing inflection-point opportunities from zero to one. Selection factors: progress with core downstream customers, sample submission and validation progress, small-batch orders landing, product performance compliance rate. Investment points: closely track certification inflection points, position ahead of validation approval, and benefit from the valuation uplift when orders land.

  3. Stock picking during the volume ramp and penetration period. The core focus is capacity release and cost control; embrace growth leaders with rapid earnings growth. Selection factors: capacity expansion progress, speed of market share gains, gross margin trend, order visibility. Investment points: take heavy positions in industry leaders, earn from earnings growth, and keep tracking the pace of profit improvement.

  4. Stock picking during the full substitution period. The core focus is industry structure and cost advantage; allocate to leading companies with global competitiveness. Selection factors: market share, cost control capability, global competitiveness, cash flow quality. Investment points: value allocation, earn from structure optimization and steady profits, and lower return expectations.

Comments

0
No comments yet.